revumenib
syndax pharma
['revumenib', 'leusm']
congress | #ash22
ghavas issa shows, in 60 patients, orr = 53%, cr/crh = 30%, and mrd-negativity rate = 56% with revumenib. median os = 7.0 months, and median duration of cr/crh = 9.1 months (n=18). #leusm
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm